Clinical Report: FDA approves XFG-adapted COVID-19 vaccine

Overview

The FDA has approved the XFG-adapted COVID-19 vaccine (COMIRNATY) for adults aged 65 and older and for individuals aged 5-64 with underlying conditions. This approval is based on data supporting the vaccine's safety and effectiveness.

Background

The approval of the XFG-adapted COVID-19 vaccine targets a variant identified as a preferred composition for vaccines in the U.S. starting in fall 2026. This decision is based on the ongoing evolution of SARS-CoV-2 variants.

Data Highlights

The approval was based on previously submitted clinical, nonclinical, and real-world data supporting the safety and effectiveness of COMIRNATY.

Key Findings

• The XFG-adapted vaccine is approved for adults aged 65 years and older and individuals aged 5-64 with at least one underlying condition.
• The approval is based on data showing immune responses against multiple circulating SARS-CoV-2 variants.
• More than 5 billion doses of COMIRNATY have been distributed globally.
• Severe allergic reactions may occur in patients with a history of such reactions to previous doses of COMIRNATY or other Pfizer-BioNTech vaccines.
• Myocarditis and pericarditis have been reported, particularly among males aged 12-24 years.
• Common adverse events include injection-site reactions, fatigue, headache, and gastrointestinal symptoms.

Clinical Implications

Healthcare providers should be aware of the updated vaccine formulation and its target populations.

Conclusion

The approval of the XFG-adapted vaccine addresses the evolving landscape of COVID-19 variants.

Related Resources & Content

1. BioNTech, FDA, 2026 -- FDA approves XFG-adapted COVID-19 vaccine
2. The ASCO Post — FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More
3. MDSpire News — Protein-Based COVID Vaccine Gains FDA Approval
4. MDSpire News — FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure
5. the asco post — FDA Approves Axatilimab-csfr for Chronic GVHD
6. FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More
7. Protein-Based COVID Vaccine Gains FDA Approval
8. FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure
9. 2025–2026 COVID-19 Vaccination Guidance | Covid | CDC
10. August 27, 2026 Approval Letter - COMIRNATY
11. Interim Effectiveness of 2025–2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States | Infectious Diseases and Therapy | Springer Nature Link